Collaboration is also extending from innovative R&D to whole-course disease management and stronger primary-care capabilities. Bayer signed a strategic partnership with the China Stroke Specialty Alliance. The two parties will deepen collaboration on whole-course management of stroke recurrence prevention and jointly advance the full "prevention, treatment, management, and rehabilitation" chain for stroke. The "2026 Prostate Cancer Quality Control Excellence Enhancement Program", hosted by the Beijing Hongyuan Charity Foundation and supported by Bayer, was also formally signed at the ninth CIIE. Aligned with the Healthy China Initiative requirements for standardized cancer diagnosis and treatment, the program is dedicated to strengthening the prostate cancer quality-control system and narrowing regional differences in care. With Bayer's support, the China Health Promotion Foundation for Human Health Science and Technology — together with heart failure experts and patient representatives — formally launched the Heart Failure Care Public Awareness Ambassador Initiative. The initiative focuses on the risk of sudden cardiac death that "stable" heart failure patients still face, aiming to promote standardized treatment and long-term management so that patients can live longer and better. Bayer also formally launched the Proteinuria Target Initiative. The event brought together leading experts in nephrology, cardiovascular medicine and endocrinology, public-interest organizations, and company representatives to explore new pathways for standardized proteinuria management in people with diabetes.
In consumer health, Bayer reached multiple collaborations around evidence-based science and channel reach to bring innovative health solutions into consumers' daily lives faster. Against a market backdrop shifting from "marketing-driven" to "evidence-driven" and from "ingredient stacking" to "science-based evidence", Bayer and Sirio Health established the "Bayer–Sirio Health Joint Laboratory Evidence-Based Research Platform" at the ninth CIIE, formally announcing deeper collaboration in nutrition and health science research and innovation translation. The joint laboratory will combine Bayer's strengths in brand, products, and consumer insights with Sirio Health's capabilities in evidence-based research, R&D validation, and innovation translation, creating an innovation-enabling platform that links scientific discovery, evidence-based validation, and commercial rollout. Leveraging CIIE as a platform, Bayer brought together industry associations, academia, and industry partners to participate in and support two thematic forums focused on innovation and development in the OTC and consumer health sectors, fostering industry consensus and dialogue on the sector's future.
